Janux Therapeutics (JANX) Net Cash Flow (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Net Cash Flow data on file, last reported at -$506000.0 in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 99.86% year-over-year to -$506000.0 in Q1 2026; TTM through Mar 2026 was -$21.9 million, a 84.24% increase from a year earlier, with the FY2025 full-year figure at -$378.3 million, down 191.95% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$506000.0, down from $3.9 million in the prior quarter.
• Over the last five years, Net Cash Flow for JANX reached as high as $403.9 million in Q4 2024 and fell as low as -$356.9 million in Q1 2025.
• Historically, Net Cash Flow has averaged $955647.1 across 5 years, with a median of $2.1 million in 2023.
• On a YoY basis, Net Cash Flow climbed as much as 19571.26% in 2024 and fell as far as 6018.19% in 2024.
• Year by year, Net Cash Flow stood at -$13.3 million in 2022, then soared by 115.41% to $2.1 million in 2023, then surged by 19571.26% to $403.9 million in 2024, then tumbled by 99.02% to $3.9 million in 2025, then sank by 112.83% to -$506000.0 in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$506000.0 in Q1 2026, $3.9 million in Q4 2025, and -$4.1 million in Q3 2025.